TruSight Oncology

TruSight Oncology is a set of NGS platform reagents for the detection of cancer variants, using an enrichment-based method to simultaneously analyze DNA and RNA. Gene content is not included.Read More...
Select Product(s)

TruSight® Oncology Library Prep



TruSight Oncology DNA Library Prep



TruSight® Oncology RNA Library Prep



TruSight® Oncology Enrichment



Product Highlights

The enrichment-based next-generation sequencing (NGS) reagents enable simultaneous analysis of DNA and RNA, and can cover a wide range of cancer variant types. The comprehensive nature of this methodology provides laboratories with a deep view into the genetics of cancer.

  • Accurate Results from Low-Quality Samples1
    Enables variant detection with as little as 40 ng DNA and RNA input, maximizing the results from precious formalin-fixed, paraffin-embedded (FFPE) samples.
  • Supports Comprehensive Coverage of Cancer-Related Variants
    Allows the assessment of multiple variant types in one assay using DNA and RNA which creates efficiencies in sample usage, time, and cost.
  • Integrated, Streamlined Workflow
    DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis.
  • Flexible Applications
    Enrichment-based workflow allows for a wide variety of content, input types, and applications.

Frequently Purchased Together


Method-Specific Workflow Example


Feature Article

Genomics Powering Access to the Latest Cancer Breakthroughs

Garret Hampton discusses how TruSight Oncology can be extended to whole-exome and -genome sequencing and sequencing RNA transcripts for profiling of cancers.

Read More

Related Products

TruSight Oncology 500

Assay targeting multiple variant types, including microsatellite instability (MSI) and tumor mutational burden (TMB).

TruSight Tumor 170

Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.

TruSight RNA Fusion Panel

Provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer research samples.

  1. Data on file. Illumina, Inc. March 2017.